Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 281–290 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 281

    Medicine slug
    ceftriaxone
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    35
    Source count
    33
    Agreement rate
    1
    Recorded readings

    1. 95%

      Numeric value
      95
      Unit
      %
      Source records
      33

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 33 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5116231f-82d1-44be-b08e-560c9a50e5c5 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86ec0a92-a552-4a6d-9125-a54f95e43392 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddbc3bf6-5bab-4851-ae5a-ef263cd8f255 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:365fc265-8e6c-432f-9fda-911f5f7fb451 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c801096-ca61-4b29-a1e1-5f7e7813b191 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d1f630b-e759-4395-9d01-ddc90e4fea75 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b642877e-0d36-4218-afe9-0a39f35b571d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf401df-bcdc-4773-a63b-9741c0f74b3d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cdf0743-c62b-4969-b9c9-4c6400644f6c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:96f3fc1e-84f4-4e9b-91ac-19a1692f227a (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de028434-46cf-44f6-8ac6-889c7c6943b3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53df951b-2eee-44b1-bae2-df7ed85bc0ed (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f8776bd-4f5b-427a-849a-6b8338f7997d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:128bb292-d174-4769-b3e6-9f16617f31e3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a937e47-8c36-4656-83e1-b3c18ed9bac3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36c07ebf-b091-483e-b2c4-f0fc0c2b4186 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cf93bc5-9e4c-4734-bc02-c7d0ac071022 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff8e830a-c288-46fb-9e19-ec2017943c07 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03283208-8616-4117-9d2b-aa8046017a4f (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac03a72c-0e35-40f9-b7fc-081badb5f19c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea1db43-40fa-417b-8911-ae98092070a0 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8351aa37-552d-471d-b293-c564dcb6ec29 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42ba7a9d-7d2b-4eac-af59-897151a8c924 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53415af6-4072-4339-83e2-d870ae02a0e2 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bed9b33-29e3-4f04-9766-43a21c7ad47a (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85ce4f8b-77e0-48bf-9f57-93f1478befa2 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:790279d4-2456-4091-abec-960b78885432 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f01cf0e5-caaf-4759-ba21-50f3aceff523 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 mcg/mL to a value of 85% bound at 300 mcg/mL.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19141ccd-e66c-49a2-a794-0616028495a7 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of < 25 mcg/mL to a value of 85% bound at 300 mcg/mL.

  2. Projected row 282

    Medicine slug
    ceftriaxone
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    35
    Source count
    35
    Agreement rate
    0.942857
    Recorded readings

    1. 5.78 to 13.5 L

      Numeric value
      5.78
      Unit
      L
      Source records
      33

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 33 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5116231f-82d1-44be-b08e-560c9a50e5c5 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86ec0a92-a552-4a6d-9125-a54f95e43392 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddbc3bf6-5bab-4851-ae5a-ef263cd8f255 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:365fc265-8e6c-432f-9fda-911f5f7fb451 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c801096-ca61-4b29-a1e1-5f7e7813b191 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d1f630b-e759-4395-9d01-ddc90e4fea75 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b642877e-0d36-4218-afe9-0a39f35b571d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf401df-bcdc-4773-a63b-9741c0f74b3d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cdf0743-c62b-4969-b9c9-4c6400644f6c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:96f3fc1e-84f4-4e9b-91ac-19a1692f227a (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de028434-46cf-44f6-8ac6-889c7c6943b3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53df951b-2eee-44b1-bae2-df7ed85bc0ed (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f8776bd-4f5b-427a-849a-6b8338f7997d (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/ hour.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:128bb292-d174-4769-b3e6-9f16617f31e3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a937e47-8c36-4656-83e1-b3c18ed9bac3 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36c07ebf-b091-483e-b2c4-f0fc0c2b4186 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cf93bc5-9e4c-4734-bc02-c7d0ac071022 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff8e830a-c288-46fb-9e19-ec2017943c07 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03283208-8616-4117-9d2b-aa8046017a4f (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac03a72c-0e35-40f9-b7fc-081badb5f19c (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea1db43-40fa-417b-8911-ae98092070a0 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8351aa37-552d-471d-b293-c564dcb6ec29 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42ba7a9d-7d2b-4eac-af59-897151a8c924 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53415af6-4072-4339-83e2-d870ae02a0e2 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bed9b33-29e3-4f04-9766-43a21c7ad47a (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85ce4f8b-77e0-48bf-9f57-93f1478befa2 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:790279d4-2456-4091-abec-960b78885432 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f01cf0e5-caaf-4759-ba21-50f3aceff523 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19141ccd-e66c-49a2-a794-0616028495a7 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour.

    2. 5.8 to 13.5 L

      Numeric value
      5.8
      Unit
      L
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cd2d96f-83e5-4326-ae87-d0ede4ba493a (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the apparent volume of distribution ranged from 5.8 to 13.5 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67153914-16bc-490d-82d7-638061618467 (opens source in a new tab)

        Ceftriaxone label

        Version not recorded · Effective date not recorded

        Over a 0.15 to 3 g dose range in healthy adult subjects, the apparent volume of distribution ranged from 5.8 to 13.5 L.

  3. Projected row 283

    Medicine slug
    celecoxib
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    139
    Source count
    137
    Agreement rate
    1
    Recorded readings

    1. 11 hours

      Numeric value
      11
      Unit
      hours
      Source records
      137

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 137 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:806e5f8a-f986-4f88-ba3e-8265f86afa48 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14e8d788-e44c-4a40-8678-25cf45fed477 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The effective half-life is approximately 11 hours under fasted conditions.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0e0243e-59b3-4f73-8c21-86b60fc7894b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce61a585-5ac0-4185-99eb-a9511cd25a98 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dc9020d-28f5-4c69-896c-87b38e3ddb88 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:862698b6-2cc9-4374-992d-024beae6eba3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:feee6a01-63f9-42c3-8bd8-ca713a08b36d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The effective half-life is approximately 11 hours under fasted conditions.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a234c0c-30a7-49f5-92a1-a1fc836ff9ae (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dea035a6-dcf1-4b7d-8adc-a2f678b71fd9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:deeecba5-7a76-444b-a891-b00b1fb16d51 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76f9bcb7-0e94-485f-816d-61d4e1ed24e0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a0db9f-174b-1603-e053-2995a90a79a3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dac05189-4acf-d6bb-e053-2a95a90a46a9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f20976d-bed3-4a06-9aaf-f5b5240e4ce3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89db0dec-3800-4d89-a765-24838f4d0c30 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0ca85fa-8b80-4a48-a1a4-a1c181821c39 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77f3b90b-a25d-4c47-975a-2a988d696a3f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:560017b1-daf8-464e-b86f-0a75c78002ec (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57b07096-6d7c-1653-e063-6294a90aa6e2 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45816eae-ad83-4d2f-a035-c3f9f24708f9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06076494-62ad-4f58-b8bb-7038fcfe3b12 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:528a6f12-9878-4005-8fc2-5997adbb287f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fbaa580-f33a-417d-e063-6294a90ad7df (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85bfe02b-bfcb-44ee-81a0-11765c3054a9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00e67d5e-df6f-4dfd-8c2d-a001c8a99af0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9da1f2-717b-32b6-e053-2995a90ae585 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50c29846-3426-0310-e054-00144ff8d46c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0de7a6f8-baba-1fd0-e063-6394a90ad434 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d14aecf5-16e9-459a-bda4-4ca8f290796a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d0dcac1-237c-47aa-bcfb-50fa20b5b838 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b06ced10-81c6-4f48-a205-1e0db228cb8b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e18d2fa4-4982-4e2a-af55-4319d6416efb (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a5ffbd-49c4-4a97-867b-2b14a3675020 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c96509cc-47f4-44f8-9f7e-4e49cc3d5348 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d12625b1-2af9-4532-af91-d40b65eeffef (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cbe21c0-3425-9a25-e063-6294a90a0d1d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:631154cd-8f61-41b2-a686-80edc711cdaa (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a1e9a52-4627-4098-8a11-25e92ad96023 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0f3aacf-df5d-dad7-e053-2995a90ac5eb (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6291230-7598-407a-aef0-ec1f09277d2a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3bc74e76-0517-69c6-e063-6394a90abe75 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac670924-0a3f-4f94-ac01-9e3c3071c990 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:951df0f7-5fb7-40f5-e053-2995a90a1edd (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e8484a8-04a6-4be3-8c5c-1883b0490d53 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7a183dc-f4d5-483f-964c-f2745a3640ad (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bf407db-8bc6-4aea-8bcc-eaa4c24cb7a6 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf49d7f-8319-4051-b7ac-fe063268b39b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9d962a-5469-2039-e053-2a95a90ad59f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8fdcc56-7a53-9a42-e053-6394a90a48d5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1abc73e-c6ab-a0a5-e053-2a95a90a0817 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7de31e90-2eaf-46cd-a058-3946b029d88c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0839895-6a36-4e4f-9336-98632b60622a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56127f57-7810-4f5d-a11d-e08fb2ed138b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd569104-8243-48fa-8e93-5a08654ad6dd (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52572bfb-43f0-4b55-b1fd-231a05c8b83e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bc96d0c-b484-3cee-e063-6294a90a9193 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a62612b3-9564-2b34-be59-6aa5ac53679c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b8e923c-253f-461e-94d7-669e75dc73e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd743d3-4821-4919-90eb-6d306ca7999f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The effective half-life is approximately 11 hours under fasted conditions.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e811c3a-5653-4617-b958-380802cc443a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f60394f5-fd69-929b-e053-2995a90a5793 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae7943ab-b1fc-f08f-e053-2995a90a051e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac87b4f9-3f66-8cf7-e053-2995a90ade0f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05224473-27dc-4f6d-a52a-c40a7af2f2f4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:265b50cc-6d99-4ef8-8439-6792e1f21c68 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27f17ae7-939b-402e-9498-3b6611104089 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e84d67c8-010d-495c-8691-ae16d0698f8d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59f495e8-3cea-9d98-e063-6394a90a89d4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b127e-c919-418f-e063-6394a90a06d0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9a7f32c-8136-4f29-be6b-4d5e904ca0f1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cbd2d6de-6f0d-4b69-8e27-a1fe08830ba5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad14a4e-2f05-4ce7-93d1-1cb7e4d8f7d0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c529b321-38ed-434f-b76e-06902cdd40dc (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The effective half-life is approximately 11 hours under fasted conditions.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85b87dd2-c609-4d69-99eb-0acd852acdaf (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0d89c39e-4858-4255-9127-1366e005203c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d6675e4-5859-4be2-8037-a20ce9f707aa (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87c16a33-5eb0-40b0-a020-ed924326f697 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f874eddf-b2f3-6830-e053-6394a90ade7a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:408b30d6-f5c2-4239-b993-d8f77a8e160b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56d64558-1fad-420e-8fcd-7103cd073127 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1ab644d-b668-3cf3-e053-2995a90addb0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c86ece8-1cf5-4688-91b1-8aef5d60b7e4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fc74af6-4573-411d-9082-f3edd44a52a4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aaa3a4f5-b281-415f-a08c-e0cefdae2fb5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9749f00-0307-4842-a95b-9a8b4989df25 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d258e065-e9a6-44e2-89c9-6892d771d9d3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c91e5933-1798-4096-9f08-fb1200e154e1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The effective half-life is approximately 11 hours under fasted conditions.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3545cfb-97c3-b896-e053-2a95a90a15a0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac5c0d72-1bb3-4065-b2f4-5516b0869775 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34bef49c-eca1-4f17-9b1b-55900ac40829 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a450db8-313c-4120-9b8e-58c956323fa4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5094d47e-f791-4190-9397-b7500143a74d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed2093f6-1606-100a-e053-2995a90a5b95 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3acbfd9-a1c2-4aa6-b5f0-013cfad6cca8 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:933532fa-044a-48b1-bbe4-28062564f98a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59cca611-c035-da50-e063-6294a90a73f5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eca923da-59fa-da2e-e053-2a95a90a6a51 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ae11faa-5bbe-49b7-a4dd-b573c304cf66 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351f5f07-bdd4-9893-e063-6394a90a7281 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0f73074-f3d8-4812-8e64-f88a02869ed3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8fdd580-09da-9c1c-e053-6394a90a4706 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69aebbab-9906-be86-e053-2991aa0aa8a5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15d6ef4f-568d-9d3e-e063-6294a90ab04c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfdc74e8-1e4e-53e1-e053-2995a90abc52 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:627abea5-e39a-4e4f-b1ab-4842ed8112e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43979279-867b-4303-8f30-fc58ae75a069 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e57bd99-5b7a-c2c7-e063-6294a90afb8c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b2ffbdb-1847-d93b-e063-6394a90a06f5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d94849a7-1831-4319-982c-c6b20dc42038 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8709cbe7-3de1-4908-a0a9-53002bcee15b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a99a67f3-ccaa-4d54-8922-d6dd30fba274 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3191c9dc-bfdf-0591-e054-00144ff8d46c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c787b0ab-77ab-4f7e-9fea-be2a0085020a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1071fcb5-0e9f-4e30-8fb4-df76fd876fe8 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8ade384-2072-2cc2-e053-2a95a90ae791 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0df546e-17c9-4e85-839d-336612d7b9e5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78ce3df5-07ee-43bb-9348-104a9524a032 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9114d6a-13d7-443c-be44-7866b4a4cf96 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d799328f-9ea0-4b64-9667-8feaa97f150c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4af52ae3-6b9d-4bc9-ad6b-c983e4c9dcc7 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5250529a-6a03-78a1-e063-6294a90a47f9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb0be640-067e-4422-9bec-d5fa07175bd0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:217265c0-e98e-482c-8af2-f8ac0ab7a0a1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a926010-08e1-44dd-bc6d-ed15374bd0d3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14962aef-7609-b29a-e063-6394a90a5399 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:550c828b-8c88-4c47-a7b8-a436aed46dc7 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95b2ced1-eca2-4c25-aa10-c9fb86b353a3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a669c28-fbc7-827c-e063-6394a90a0829 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c213e224-c2fb-726e-e053-2a95a90a21c5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dabfb290-0a7f-3429-e053-2a95a90ae04c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:643e177f-216d-4dfa-824a-7516a488304e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47be1d99-eebb-42f9-80d9-291a024b1364 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6000132-ac6c-4b61-a98a-8cc2dd84b3f0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35d9494-4190-41a8-80d4-c9d877c432e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a1eadd5-c0a7-473e-bde0-6b9450d11c95 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78d59905-4a78-4d9f-ac29-58790a5b3a92 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5d0e5b9-97d8-42a4-a0a0-c09dde7008e6 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours.

  4. Projected row 284

    Medicine slug
    celecoxib
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    139
    Source count
    2
    Agreement rate
    0.5
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8a5de07-9f27-4a54-a885-8089f0307bd7 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        Absorption Following administration of 120 mg of ELYXYB under fasting condition in 24 healthy subjects, the median time to peak plasma levels (i.e., T max ) of celecoxib was 1 hour (range 0.67 to 3.00).

    2. 1.5 hours

      Numeric value
      1.5
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5094d47e-f791-4190-9397-b7500143a74d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        Absorption Following a single dose administration of 200 mg VYSCOXA and 200 mg celecoxib capsules under fasting condition in 52 healthy subjects, the median time to peak plasma levels (i.e.,Tmax) of celecoxib was 1.5 hours (range 0.67 – 8.00 hours) and 2.5 hours (range 1.00 – 8.00 hours), respectively.

  5. Projected row 285

    Medicine slug
    celecoxib
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    139
    Source count
    137
    Agreement rate
    1
    Recorded readings

    1. 400 L

      Numeric value
      400
      Unit
      L
      Source records
      137

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 137 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:806e5f8a-f986-4f88-ba3e-8265f86afa48 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14e8d788-e44c-4a40-8678-25cf45fed477 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0e0243e-59b3-4f73-8c21-86b60fc7894b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce61a585-5ac0-4185-99eb-a9511cd25a98 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dc9020d-28f5-4c69-896c-87b38e3ddb88 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:862698b6-2cc9-4374-992d-024beae6eba3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:feee6a01-63f9-42c3-8bd8-ca713a08b36d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is 1 approximately 400 L, suggesting extensive distribution into the tissues.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a234c0c-30a7-49f5-92a1-a1fc836ff9ae (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dea035a6-dcf1-4b7d-8adc-a2f678b71fd9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:deeecba5-7a76-444b-a891-b00b1fb16d51 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76f9bcb7-0e94-485f-816d-61d4e1ed24e0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a0db9f-174b-1603-e053-2995a90a79a3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dac05189-4acf-d6bb-e053-2a95a90a46a9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f20976d-bed3-4a06-9aaf-f5b5240e4ce3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89db0dec-3800-4d89-a765-24838f4d0c30 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0ca85fa-8b80-4a48-a1a4-a1c181821c39 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77f3b90b-a25d-4c47-975a-2a988d696a3f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:560017b1-daf8-464e-b86f-0a75c78002ec (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57b07096-6d7c-1653-e063-6294a90aa6e2 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45816eae-ad83-4d2f-a035-c3f9f24708f9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06076494-62ad-4f58-b8bb-7038fcfe3b12 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:528a6f12-9878-4005-8fc2-5997adbb287f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fbaa580-f33a-417d-e063-6294a90ad7df (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85bfe02b-bfcb-44ee-81a0-11765c3054a9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00e67d5e-df6f-4dfd-8c2d-a001c8a99af0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9da1f2-717b-32b6-e053-2995a90ae585 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50c29846-3426-0310-e054-00144ff8d46c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0de7a6f8-baba-1fd0-e063-6394a90ad434 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d14aecf5-16e9-459a-bda4-4ca8f290796a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d0dcac1-237c-47aa-bcfb-50fa20b5b838 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b06ced10-81c6-4f48-a205-1e0db228cb8b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e18d2fa4-4982-4e2a-af55-4319d6416efb (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a5ffbd-49c4-4a97-867b-2b14a3675020 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c96509cc-47f4-44f8-9f7e-4e49cc3d5348 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d12625b1-2af9-4532-af91-d40b65eeffef (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cbe21c0-3425-9a25-e063-6294a90a0d1d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:631154cd-8f61-41b2-a686-80edc711cdaa (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a1e9a52-4627-4098-8a11-25e92ad96023 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0f3aacf-df5d-dad7-e053-2995a90ac5eb (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6291230-7598-407a-aef0-ec1f09277d2a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3bc74e76-0517-69c6-e063-6394a90abe75 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac670924-0a3f-4f94-ac01-9e3c3071c990 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:951df0f7-5fb7-40f5-e053-2995a90a1edd (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e8484a8-04a6-4be3-8c5c-1883b0490d53 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7a183dc-f4d5-483f-964c-f2745a3640ad (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bf407db-8bc6-4aea-8bcc-eaa4c24cb7a6 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf49d7f-8319-4051-b7ac-fe063268b39b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af9d962a-5469-2039-e053-2a95a90ad59f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8fdcc56-7a53-9a42-e053-6394a90a48d5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1abc73e-c6ab-a0a5-e053-2a95a90a0817 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7de31e90-2eaf-46cd-a058-3946b029d88c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0839895-6a36-4e4f-9336-98632b60622a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56127f57-7810-4f5d-a11d-e08fb2ed138b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd569104-8243-48fa-8e93-5a08654ad6dd (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52572bfb-43f0-4b55-b1fd-231a05c8b83e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bc96d0c-b484-3cee-e063-6294a90a9193 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a62612b3-9564-2b34-be59-6aa5ac53679c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b8e923c-253f-461e-94d7-669e75dc73e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd743d3-4821-4919-90eb-6d306ca7999f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e811c3a-5653-4617-b958-380802cc443a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f60394f5-fd69-929b-e053-2995a90a5793 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae7943ab-b1fc-f08f-e053-2995a90a051e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac87b4f9-3f66-8cf7-e053-2995a90ade0f (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05224473-27dc-4f6d-a52a-c40a7af2f2f4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:265b50cc-6d99-4ef8-8439-6792e1f21c68 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27f17ae7-939b-402e-9498-3b6611104089 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e84d67c8-010d-495c-8691-ae16d0698f8d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59f495e8-3cea-9d98-e063-6394a90a89d4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b127e-c919-418f-e063-6394a90a06d0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9a7f32c-8136-4f29-be6b-4d5e904ca0f1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cbd2d6de-6f0d-4b69-8e27-a1fe08830ba5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad14a4e-2f05-4ce7-93d1-1cb7e4d8f7d0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c529b321-38ed-434f-b76e-06902cdd40dc (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85b87dd2-c609-4d69-99eb-0acd852acdaf (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0d89c39e-4858-4255-9127-1366e005203c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d6675e4-5859-4be2-8037-a20ce9f707aa (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87c16a33-5eb0-40b0-a020-ed924326f697 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f874eddf-b2f3-6830-e053-6394a90ade7a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:408b30d6-f5c2-4239-b993-d8f77a8e160b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56d64558-1fad-420e-8fcd-7103cd073127 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1ab644d-b668-3cf3-e053-2995a90addb0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c86ece8-1cf5-4688-91b1-8aef5d60b7e4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fc74af6-4573-411d-9082-f3edd44a52a4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aaa3a4f5-b281-415f-a08c-e0cefdae2fb5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9749f00-0307-4842-a95b-9a8b4989df25 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d258e065-e9a6-44e2-89c9-6892d771d9d3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c91e5933-1798-4096-9f08-fb1200e154e1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3545cfb-97c3-b896-e053-2a95a90a15a0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac5c0d72-1bb3-4065-b2f4-5516b0869775 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34bef49c-eca1-4f17-9b1b-55900ac40829 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a450db8-313c-4120-9b8e-58c956323fa4 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5094d47e-f791-4190-9397-b7500143a74d (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed2093f6-1606-100a-e053-2995a90a5b95 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b3acbfd9-a1c2-4aa6-b5f0-013cfad6cca8 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:933532fa-044a-48b1-bbe4-28062564f98a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59cca611-c035-da50-e063-6294a90a73f5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eca923da-59fa-da2e-e053-2a95a90a6a51 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ae11faa-5bbe-49b7-a4dd-b573c304cf66 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:351f5f07-bdd4-9893-e063-6394a90a7281 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0f73074-f3d8-4812-8e64-f88a02869ed3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8fdd580-09da-9c1c-e053-6394a90a4706 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69aebbab-9906-be86-e053-2991aa0aa8a5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15d6ef4f-568d-9d3e-e063-6294a90ab04c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfdc74e8-1e4e-53e1-e053-2995a90abc52 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:627abea5-e39a-4e4f-b1ab-4842ed8112e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43979279-867b-4303-8f30-fc58ae75a069 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e57bd99-5b7a-c2c7-e063-6294a90afb8c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b2ffbdb-1847-d93b-e063-6394a90a06f5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d94849a7-1831-4319-982c-c6b20dc42038 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8709cbe7-3de1-4908-a0a9-53002bcee15b (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a99a67f3-ccaa-4d54-8922-d6dd30fba274 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3191c9dc-bfdf-0591-e054-00144ff8d46c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c787b0ab-77ab-4f7e-9fea-be2a0085020a (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1071fcb5-0e9f-4e30-8fb4-df76fd876fe8 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8ade384-2072-2cc2-e053-2a95a90ae791 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0df546e-17c9-4e85-839d-336612d7b9e5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78ce3df5-07ee-43bb-9348-104a9524a032 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9114d6a-13d7-443c-be44-7866b4a4cf96 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d799328f-9ea0-4b64-9667-8feaa97f150c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4af52ae3-6b9d-4bc9-ad6b-c983e4c9dcc7 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5250529a-6a03-78a1-e063-6294a90a47f9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb0be640-067e-4422-9bec-d5fa07175bd0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:217265c0-e98e-482c-8af2-f8ac0ab7a0a1 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a926010-08e1-44dd-bc6d-ed15374bd0d3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14962aef-7609-b29a-e063-6394a90a5399 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:550c828b-8c88-4c47-a7b8-a436aed46dc7 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95b2ced1-eca2-4c25-aa10-c9fb86b353a3 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a669c28-fbc7-827c-e063-6394a90a0829 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c213e224-c2fb-726e-e053-2a95a90a21c5 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dabfb290-0a7f-3429-e053-2a95a90ae04c (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:643e177f-216d-4dfa-824a-7516a488304e (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47be1d99-eebb-42f9-80d9-291a024b1364 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6000132-ac6c-4b61-a98a-8cc2dd84b3f0 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35d9494-4190-41a8-80d4-c9d877c432e9 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a1eadd5-c0a7-473e-bde0-6b9450d11c95 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78d59905-4a78-4d9f-ac29-58790a5b3a92 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5d0e5b9-97d8-42a4-a0a0-c09dde7008e6 (opens source in a new tab)

        Celecoxib label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state (V ss /F) is approximately 400 L, suggesting extensive distribution into the tissues.

  6. Projected row 286

    Medicine slug
    cetirizine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    393
    Source count
    20
    Agreement rate
    1
    Recorded readings

    1. 93%

      Numeric value
      93
      Unit
      %
      Source records
      20

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 20 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dc7107-a2d2-4519-ac6f-cbed9f07e9bf (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a03d33dc-a84c-4ab7-88a8-77333bfcb8e7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1,000 ng/mL, which includes the therapeutic plasma levels observed.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f47dbc5-dfb4-425c-9fe4-777fa3c4e72e (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aeb73ab9-3b05-4062-a7fd-352cf2094a56 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05324e41-ee3f-0e4b-e063-6294a90a102c (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e94be37-0971-44b3-9857-f56330d810b6 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d81446e-f713-4ca4-af38-3d31cf618873 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f33e859d-ebc9-4d4f-a57d-204c48760d20 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e874264a-becc-45d0-b934-779eab5f5085 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e626bd59-dd18-465c-b740-9d04eb48c28e (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:365cbabe-535b-4c34-852b-6cd63782e3e5 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 ng/mL to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ed61888-4b22-4e11-96e7-f70aa516db4f (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c6a440b-bd0f-414b-bab3-3b2f57c479d7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1,000 ng/mL, which includes the therapeutic plasma levels observed.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:573770f6-b76e-f6ba-e063-6294a90aa54d (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9b21d71-106e-4bd5-aaab-9254c8a44e0d (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b5908f1-faba-c317-e063-6294a90aa8a7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d7af88-87b4-370e-e063-6294a90a8af6 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution : The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25–1000 ng/mL, which includes the therapeutic plasma levels observed.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efabbad5-a162-45c8-a896-5af58e5d2d39 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0956baea-f0ad-4aac-9464-831840db9230 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71448ab0-e23e-4cf7-940e-7d67e7362fb4 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed.

  7. Projected row 287

    Medicine slug
    cetirizine
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    393
    Source count
    20
    Agreement rate
    0.9
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      18

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 18 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dc7107-a2d2-4519-ac6f-cbed9f07e9bf (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or syrup in adults.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a03d33dc-a84c-4ab7-88a8-77333bfcb8e7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f47dbc5-dfb4-425c-9fe4-777fa3c4e72e (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following oral administration of tablets or solution in adults.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aeb73ab9-3b05-4062-a7fd-352cf2094a56 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max) of approximately 1 hour following oral administration of tablets or syrup in adults.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05324e41-ee3f-0e4b-e063-6294a90a102c (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e94be37-0971-44b3-9857-f56330d810b6 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d81446e-f713-4ca4-af38-3d31cf618873 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e874264a-becc-45d0-b934-779eab5f5085 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following oral administration of tablets or solution in adults.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e626bd59-dd18-465c-b740-9d04eb48c28e (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:365cbabe-535b-4c34-852b-6cd63782e3e5 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following administration of oral solution in adults.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ed61888-4b22-4e11-96e7-f70aa516db4f (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c6a440b-bd0f-414b-bab3-3b2f57c479d7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9b21d71-106e-4bd5-aaab-9254c8a44e0d (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or syrup in adults.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b5908f1-faba-c317-e063-6294a90aa8a7 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d7af88-87b4-370e-e063-6294a90a8af6 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or solution in adults.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efabbad5-a162-45c8-a896-5af58e5d2d39 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or oral solution in adults.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0956baea-f0ad-4aac-9464-831840db9230 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or solution in adults.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71448ab0-e23e-4cf7-940e-7d67e7362fb4 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or solution in adults.

    2. 0.06 hour

      Numeric value
      0.06
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f33e859d-ebc9-4d4f-a57d-204c48760d20 (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Peak concentrations were reached at 0.06 hour (range 0.03 to 0.07 hour) and 0.03 hour (range 0.03 to 2.00 hour) for cetirizine hydrochloride 5 mg and 10 mg IV injection, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:573770f6-b76e-f6ba-e063-6294a90aa54d (opens source in a new tab)

        Cetirizine label

        Version not recorded · Effective date not recorded

        Peak concentrations were reached at 0.06 hour (range 0.03 to 0.07 hour) and 0.03 hour (range 0.03 to 2.00 hour) for cetirizine hydrochloride 5 mg and 10 mg IV injection, respectively.

  8. Projected row 288

    Medicine slug
    cetrorelix
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 86%

      Numeric value
      86
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aca7768e-28a7-4027-b1d8-e66247665f79 (opens source in a new tab)

        Cetrorelix label

        Version not recorded · Effective date not recorded

        In vitro protein binding to human plasma is 86%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b3057ac-6cac-4509-a355-df76247b992c (opens source in a new tab)

        Cetrorelix label

        Version not recorded · Effective date not recorded

        In vitro protein binding to human plasma is 86%.

  9. Projected row 289

    Medicine slug
    cevimeline
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    19
    Source count
    19
    Agreement rate
    0.526316
    Recorded readings

    1. 5+/-1 hours

      Numeric value
      5
      Unit
      hours
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:990887c1-11ce-4a73-83b4-0ffc5a900c85 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7432a48-1142-431e-997f-8419dc724824 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51307f82-66f2-41c7-80ff-174d7e50f7ee (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d08d8aa5-76a4-417a-a308-7d195865522f (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bcaaec18-4ee1-4cfd-84da-8fe3b8c54fc4 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe30c870-a060-4a5b-ae61-6a9933854419 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71ada1b0-3344-4202-9277-57f1a37402c1 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fbcf1a7-5b8b-42fb-b764-4b529e7d1a99 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4bd942a-1339-40c5-8fd4-850da5a69635 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1167360c-7e0f-4619-9d1a-ad4ee56cab71 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+/-1 hours.

    2. 1hours

      Numeric value
      1
      Unit
      hours
      Source records
      9

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 9 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fa69ad5-7fa7-4078-9328-aacbb0d145a4 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61dd5ee1-cf89-43ea-ada4-4e4a4d9d133b (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efc2bb24-4dda-4781-bef5-fcd9abf082dd (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f15cb50-5917-c928-e063-6294a90ab284 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dac32a9b-05b8-42c2-9a29-d885a9279456 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b429ea7-1c7c-47a4-803c-2546736f5c36 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75ae16d6-8822-4581-b747-ae894a45cdea (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca0409bc-2685-4ffd-b806-04898902a597 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:773a19e8-4c3e-4414-99a6-aea98c9790ee (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Excretion: The mean half-life of cevimeline is 5+ /-1 hours.

  10. Projected row 290

    Medicine slug
    cevimeline
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    19
    Source count
    19
    Agreement rate
    0.947368
    Recorded readings

    1. 1.5 to 2 hours

      Numeric value
      1.5
      Unit
      hours
      Source records
      18

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 18 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:990887c1-11ce-4a73-83b4-0ffc5a900c85 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7432a48-1142-431e-997f-8419dc724824 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fa69ad5-7fa7-4078-9328-aacbb0d145a4 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokine tics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51307f82-66f2-41c7-80ff-174d7e50f7ee (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61dd5ee1-cf89-43ea-ada4-4e4a4d9d133b (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d08d8aa5-76a4-417a-a308-7d195865522f (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efc2bb24-4dda-4781-bef5-fcd9abf082dd (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokine tics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bcaaec18-4ee1-4cfd-84da-8fe3b8c54fc4 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dac32a9b-05b8-42c2-9a29-d885a9279456 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokine tics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe30c870-a060-4a5b-ae61-6a9933854419 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b429ea7-1c7c-47a4-803c-2546736f5c36 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75ae16d6-8822-4581-b747-ae894a45cdea (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71ada1b0-3344-4202-9277-57f1a37402c1 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fbcf1a7-5b8b-42fb-b764-4b529e7d1a99 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca0409bc-2685-4ffd-b806-04898902a597 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4bd942a-1339-40c5-8fd4-850da5a69635 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:773a19e8-4c3e-4414-99a6-aea98c9790ee (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokine tics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1167360c-7e0f-4619-9d1a-ad4ee56cab71 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 to 2 hours.

    2. 1.5 hours

      Numeric value
      1.5
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f15cb50-5917-c928-e063-6294a90ab284 (opens source in a new tab)

        Cevimeline label

        Version not recorded · Effective date not recorded

        Pharmacokinetics Absorption: After administration of a single 30 mg capsule, cevimeline was rapidly absorbed with a mean time to peak concentration of 1.5 hours to 2 hours.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=280

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy